Development of SC-43 derivatives as a potent SHP-1 agonist to treat Hepatocellular carcinoma cell

Development of SC-43 derivatives as a potent SHP-1 agonist to treat Hepatocellular carcinoma cell

碩士 === 國立陽明大學 === 生物藥學研究所 === 104

Bibliographic Details
Main Authors:	Kai-Ting Yang, 楊凱婷
Other Authors:	Chung-Wai Shiau
Format:	Others
Language:	zh-TW
Published:	2016
Online Access:	http://ndltd.ncl.edu.tw/handle/29371565086809663211

Similar Items

Design and Synthesis of Novel Sorafenib Derivatives as SHP-1 Agonist in Hepatocellular Carcinoma
by: I-Chieh Hsu, et al.
Published: (2013)

Design, Synthesis, and Biological Evaluation of SHP-1 Agonists against Hepatocellular Carcinoma
by: Wei-Pei Xu, et al.
Published: (2015)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma
by: Jung-Chen Su, et al.
Published: (2014-07-01)

Synthesis of obatoclax analogues as SHP-1 enhancers for hepatocellular carcinoma
by: Szu-Hsien Wu, et al.
Published: (2013)

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
by: Tung-Hung Su, et al.
Published: (2017-05-01)

Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma.
by: Ewa Wilczek, et al.
Published: (2012-01-01)

The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1
by: Chen-Hong Ding, et al.
Published: (2018-02-01)

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells
by: Chiu CM, et al.
Published: (2018-03-01)

The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer
by: Gu J, et al.
Published: (2015-08-01)

Hepatocellular carcinoma-produced TLR4 agonists in tumor microenvironment
by: Ying-ying Lee, et al.
Published: (2015)

A Potent and Site-Selective Agonist of TRPA1
by: Takaya, Junichiro
Published: (2016)

Modulating RFX1-SHP1-STAT3 signaling axis by a small molecule provides a therapeutic option for hepatocellular carcinoma
by: Jung-Chen Su, et al.
Published: (2014)

Production and separation of 43Sc for radiopharmaceutical purposes
by: Katharina A. Domnanich, et al.
Published: (2017-11-01)

Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma.
by: Yingjian Liang, et al.
Published: (2011-01-01)

Liensinine suppresses STAT3-dependent HK2 expression through elevating SHP-1 to induce apoptosis in hepatocellular carcinoma cells in vitro and in vivo
by: Guangwen Shu, et al.
Published: (2018-06-01)

Novel 2-mercapto imidazole and triazole derivatives as potent TGR5 receptor agonists
by: Sameer Agarwal, et al.
Published: (2019-03-01)

Hepatocellular carcinoma cells-secreted Cystatin-C as TLR4 agonist
by: Wei-Lin Chen, et al.
Published: (2017)

MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma
by: Li Zhou, et al.
Published: (2017-02-01)

Effectiveness of Positioning on Back Pain After Transcatheter Arterial Chemoembolization Among Patients with Hepatocellular Carcinoma
by: Kai-Ting Chang, et al.
Published: (2019)

Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma
by: Yu-Yun Shao, et al.
Published: (2019-09-01)

Goniothalamin Induceed DNA Damage and Apoptosis inHepatocellular Carcinoma Derived Cells
by: Yu-ting Huang, et al.
Published: (2010)

Secreted TRAIL gene‐modified adipose‐derived stem cells exhibited potent tumor‐suppressive effect in hepatocellular carcinoma cells
by: Zhuo Liu, et al.
Published: (2021-03-01)

Discovery of a novel potent peptide agonist to adiponectin receptor 1.
by: Sunghwan Kim, et al.
Published: (2018-01-01)

A potent peptide as adiponectin receptor 1 agonist to against fibrosis
by: Lingman Ma, et al.
Published: (2017-01-01)

The role of DKK1 in hepatocellular carcinoma treated with sorafenib
by: Chun-Yi Jiang, et al.
Published: (2014)

Hepatocellular carcinoma in Brazil: report of a national survey (Florianópolis, SC, 1995)
by: GONÇALVES Carlos S., et al.
Published: (1997-01-01)

Shp1 in Solid Cancers and Their Therapy
by: Alessia Varone, et al.
Published: (2020-06-01)

Lack of expression phosphotyrosinephosphatase SHP-1 in K562 cells results from hypermethylation of the SHP-1 promoter
by: Lin-Ya Tang, et al.
Published: (2002)

Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
by: Chris Jopling, et al.
Published: (2007-12-01)

Structure-based discovery of potent and selective melatonin receptor agonists
by: Nilkanth Patel, et al.
Published: (2020-03-01)

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists
by: Edina Szűcs, et al.
Published: (2020-02-01)

Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
by: Sarita Saraswati, et al.
Published: (2019-10-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

How to Treat Hepatocellular Carcinoma in Elderly Patients
by: Piera Federico, et al.
Published: (2021-03-01)

Interleukin-3 (IL-3) signal transduction in haemopoietic cells : the role of SHP-1, SHP-2, and SHC
by: Bone, Heather Karyn
Published: (1999)

Semisynthetic Quercetin Derivatives with Potent Antitumor Activity in Colon Carcinoma
by: Ayan Mukherjee, et al.
Published: (2019-04-01)

Studies on the regulatory mechanisms of GTN-induced protein kinase inhibitors in hepatocellular carcinoma-derived cells
by: Yu-Ting Peng, et al.
Published: (2014)

Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-b][1,4]oxazine derivatives as potent GPR 119 agonists
by: Yuanying Fang, et al.
Published: (2020-01-01)

Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.
by: Huiqing Lv, et al.
Published: (2016-01-01)

Application of Pharmacoinformatics: Discovery of Potent AMP-activated Protein Kinase Agonists by Docking, Pharmacophore Analysis, and Virtual Screening
by: Jhao-Guei Yang, et al.
Published: (2008)